Ranbaxy Provides Relief Services To Victims Of Hurricane Katrina

Ranbaxy Laboratories Limited (RLL), today announced that the Company's wholly owned subsidiary, Ranbaxy Pharmaceuticals Inc. (RPI), USA, has entered into a joint initiative with the City of Jacksonville, Florida, USA, and the Association of Firefighters, Local 122 (also of Jacksonville, Florida). The objective of this cooperative effort will be to provide relief services to victims of Hurricane Katrina that caused widespread destruction in the states of Louisiana, Mississippi, and Alabama last week. This natural disaster has left a number of people homeless and in need of medical care and treatment, which challenges and exceeds the immediate support that could be provided by federal, state and local authorities.


RPI responded to the call for support from the Firefighters Association who solicited the involvement of local businesses. Chief Larry Peterson, Divisional Chief of the Jacksonville Fire Department, welcomed RPI's involvement in support of the 100 firefighters already on the scene, that were in need of food, water, and medical supplies. RPI's support consisted of pharmaceutical products, primarily anti-infectives, that could be dispensed by medical personnel to people injured as a result of the hurricane.


Five full scale engines and five rescue vehicles have since been dispatched to the areas in need. According to Chief Peterson, "A total of fifteen (19) semi-trailers carrying food and supplies are being sent over the next few days, including the RPI manufactured pharmaceutical products. RPI has donated a number of FDA approved products in trade packages, which include: Cephalosporin, Semi-synthetic Penicillin, Quinolone anti-infectives, as well as Cardiovascular, Gastrointestinal and Oral Hypoglycemic agents. In total, 17,000 bottles of such agents will be available to the victims in a matter of a few days.


Chief Peterson mentioned that "…these pharmaceutical products will be put to good use by the firefighters who are working along side of medical personnel providing care to the hurricane victims. We welcome the donation and are happy to have the support of the Ranbaxy organization that has its U.S. Distribution Center in Jacksonville, Florida. This team effort is critical during the time of such a disaster, where combined skills, talents and products can assist people left in such dire straits".


According to Dipak Chattaraj, President of Ranbaxy's U.S. operations, "We found the right partners in Jacksonville, and without hesitation, we knew we needed to make an immediate contribution to this humanitarian effort. We felt helpless like many Americans in viewing this catastrophe, but with the help of the City of Jacksonville and Firefighters Local 122, we were able to make a contribution to provide solace to the unfortunate victims of Hurricane Katrina."


Future efforts to provide support are now being discussed with all involved organizations, since it is anticipated that ongoing support will be needed into the foreseeable future.















Ranbaxy Pharmaceuticals Inc. ("RPI") based in Jacksonville, Florida, is a wholly owned subsidiary of Ranbaxy Laboratories Limited ("RLL"), India's largest pharmaceutical company. RPI is engaged in the sale and distribution of generic and branded prescription products in the U.S. healthcare system.


Ranbaxy Laboratories Limited, headquartered in India, is an integrated, research based, international pharmaceutical company producing a wide range of quality, affordable generic medicines, trusted by healthcare professionals and patients across geographies. Ranbaxy's continued focus on R&D has resulted in several approvals in developed markets and significant progress in New Drug Discovery Research. The Company's foray into Novel Drug Delivery Systems has led to proprietary "platform technologies", resulting in a number of products under development. The Company is serving its customers in over 100 countries and has an expanding international portfolio of affiliates, joint ventures and alliances, ground operations in 44 countries and manufacturing operations in 7 countries .


For further information please contact:


Ramesh L. Adige

Whole-time Director- Corporate Affairs and Global Corporate Communications

Ranbaxy Laboratories Ltd.

Plot 90, Sector 32, Gurgaon

Haryana - 122001, India

Tel: +91-124-5135000

e-mail: ramesh.adigeranbaxy

or

Raghu Kochar

Director-Corporate Communications

Ranbaxy Laboratories Ltd.

Plot 90, Sector 32, Gurgaon

Haryana - 122001, India

Tel: +91-124-5135141

e-mail: raghu.kocharranbaxy

or

Krishnan Ramalingam

Manager- Corporate Communications

Ranbaxy Laboratories Ltd.

Plot 90, Sector 32, Gurgaon

Haryana - 122001, India

Tel: +91-124-5135143

e-mail: krishnan.ramalingamranbaxy


ranbaxy